'Plucking our way up that list': Bayer highlights oncology ambitions in new Kendall Square labs
It’s been just a few months since Bayer opened its new $140 million oncology research and innovation center in Cambridge, MA, just down the road from its old Kendall Square digs. Now it’s all hands on deck to beef up the pipeline — and that means deals are coming, according to global oncology head Christine Roth.
Though the pharma giant is still holding its cards close to the vest, Roth told Endpoints News on Wednesday that she’s most interested right now “in that Phase I-plus space.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.